Does DNCB therapy potentiate epicutaneous sensitization to non-related contact allergens?
D000293:Adolescent; D000328:Adult; D000506:Alopecia Areata / Q000188:drug therapy; D000875:Anthralin / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D003877:Dermatitis, Contact / Q000209:etiology*; D004137:Dinitrochlorobenzene / Q000009:adverse effects* / Q000627:therapeutic use; D003875:Drug Eruptions / Q000209:etiology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009578:Nitrobenzenes / Q000009:adverse effects*
D004137:Dinitrochlorobenzene; D009578:Nitrobenzenes; D000875:Anthralin